Latest / Community Health Media
Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment
In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab deruxtecan (T-DXd) has fundamentally restructured therapeutic strategies across HER2-positive and HER2-low disease, while “curing” what was once thought to be really aggressive disease. From the transformative DESTINY-Breast trials to the evolving art of real-world clinical decision-making, they dissect not only the science and trial data but the shifting frameworks now guiding oncologists at the bedside.
They critically examine how T-DXd…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.